Lenzilumab
- Product Name
- Lenzilumab
- CAS No.
- 1229575-09-0
- Chemical Name
- Lenzilumab
- Synonyms
- Lenzilumab;Lenzilumab (anti-GM-CSF);Research Grade Lenzilumab;Research Grade Lenzilumab(DHC06703)
- CBNumber
- CB18080915
- Formula Weight
- 0
- MOL File
- Mol file
Lenzilumab Property
- form
- Liquid
- color
- Colorless to light yellow
Lenzilumab Chemical Properties,Usage,Production
Uses
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2].
in vivo
Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice[1].
| Animal Model: | NSG mice with CART19 cells[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; daily; 10 days |
| Result: | Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI). |
References
[1] Rosalie M Sterner, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697-709. DOI:10.1182/blood-2018-10-881722
[2] Zelalem Temesgen, et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov;95(11):2382-2394. DOI:10.1016/j.mayocp.2020.08.038
Lenzilumab Preparation Products And Raw materials
Raw materials
Preparation Products
Lenzilumab Suppliers
- Tel
- +1-781-999-5354;
- support@targetmol.com
- Country
- United States
- ProdList
- 39035
- Advantage
- 58